Table 3.
Current use of β-blockers and risk of hip/femur fractures in patient subgroups
| Current use of β-blockers | GPRD | PHARMO RLS | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases (%) | Controls (%) | Crude OR (95% CI) | Adjusted OR (95% CI)a | Cases (%) | Controls (%) | Crude OR (95% CI) | Adjusted OR (95% CI)a | |
| Gender | ||||||||
| Men | 3.4 | 4.5 | 0.68 (0.55–0.84) | 0.77 (0.60–0.98) | 10.1 | 12.0 | 0.83 (0.70–0.98) | 0.77 (0.64–0.93) |
| Women | 4.8 | 6.3 | 0.71 (0.64–0.78) | 0.83 (0.74–0.93) | 13.3 | 14.4 | 0.93 (0.95–1.02) | 0.90 (0.82–1.00) |
| Age (years) | ||||||||
| <65 | 2.9 | 3.1 | 0.93 (0.68–1.26) | 0.91 (0.62–0.91) | 5.0 | 7.2 | 1.04 (0.80–1.35) | 0.94 (0.70–1.27) |
| 65–80 | 7.0 | 9.1 | 0.71 (0.62–0.80) | 0.84 (0.73–0.98) | 14.5 | 16.8 | 0.84 (0.58–1.12) | 0.80 (0.70–0.91) |
| 80+ | 3.5 | 4.6 | 0.65 (0.57–0.75) | 0.77 (0.66–0.91) | 12.4 | 13.5 | 0.94 (0.84–1.06) | 0.94 (0.83–1.07) |
| History of any use of other antihypertensive drugs | ||||||||
| No | 2.2 | 2.4 | 0.89 (0.77–1.04) | 0.97 (0.82–1.14) | 8.3 | 8.1 | 1.02 (0.85–1.23) | 1.01 (0.90–1.14) |
| Yes | 9.7 | 14.7 | 0.60 (0.53–0.67) | 0.73 (0.64–0.83) | 20.9 | 26.9 | 0.73 (0.65–0.83) | 0.76 (0.67–0.86) |
a Adjusted for use of other antihypertensive drugs and general risk factors for falls and fractures (see Materials and Methods) Percentages represent the proportion of current beta-blocker within each subcategory (e.g. male gender)